CHICAGO -- The bispecific T-cell engager tarlatamab (Imdelltra) significantly prolonged survival in the second-line treatment ...

Amgen AMGN announced encouraging new data from its interim analysis of the global late-stage study evaluating Imdelltra ...

Amgen has detailed a positive phase 3 readout for its T-cell engager Imdelltra in previously treated small cell lung cancer ...

Imdelltra improved survival and quality of life versus chemotherapy as second-line treatment for small cell lung cancer, ...

In the Phase III IMforte trial, Tecentriq (atezolizumab) and Zepzelca (lurbinectedin) reduced the risk of disease progression ...

Jazz Pharmaceuticals plc (NASDAQ:JAZZ) announced today that the Phase 3 IMforte trial has established a new milestone in the ...

Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY) announced today positive results from the Phase III ...

Analysts said the data suggest “a strong treatment effect.” Jazz has filed for FDA approval for the combination, which could ...

Late-stage trials showed that Tecentriq combined with lurbinectedin led to a 46% reduction in the risk of the disease ...

The phase 3 IMforte study randomised adults with extensive-stage SCLC to receive Roche’s PD-L1 inhibitor Tecentriq ...

BMS will co-develop and co-commercialize BioNTech’s bispecific antibody BNT327 for solid tumors in a deal worth up to $11.1B ...

Amgen (NASDAQ:AMGN) today announced new interim results from the global Phase 3 DeLLphi-304 trial showing IMDELLTRA® (tarlatamab-dlle) reduced the risk of death by 40% and significantly extended ...